Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025Cyprium is eligible to receive royalties and up to $129 ...

The FDA has granted priority review to an NDA for taletrectinib in the treatment of advanced ROS1-positive non–small cell ...

Significant advancements in lung cancer treatment were seen throughout 2024, from new drug approvals to promising clinical ...

A first-in-class pain med and blockbusters with new indications are just a few of the possible approvals to keep an eye on in ...

On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...

This story first appeared in Colorado Newsline. Coloradans will soon be able to take psychedelic mushrooms in a regulated ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Precigen submits BLA for PRGN-2012 gene therapy targeting RRP, a rare and life-threatening condition with no cure.

The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...

Verastem's pipeline's emphasis is on RAS/MAPK-driven tumors, so the FDA's ruling might have a major influence on their ...

The upside in Precigen's stock comes after it completes the rolling submission of an FDA filing for its first potentially marketed product.

INR:3372. galaxy casino macau Roche's mosunetuzumab receives FDA breakthrough therapy designation for follicular lymphoma R&D Daily丨FDA approves Avitinib to ...